KC
PACB icon

Kepos Capital’s Pacific Biosciences PACB Stock Holding History

Kepos Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-141,543
Closed -$488K – 287
2020
Q2 		$488K Hold
141,543
– – 0.06% 146
2020
Q1 		$433K Buy
+141,543
New +$580K 0.09% 113

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Kepos Capital's PACB Position: Q3 2020 in Review

Kepos Capital sold out of Pacific Biosciences (PACB) in Q3 2020, closing a stake of 141,543 shares — an estimated $488K sold.

Kepos Capital first reported a position in PACB in Q1 2020 and held it in 2 quarters. The position peaked at $488K in Q2 2020. 174 funds tracked by Wall St. Rank hold PACB as of Q3 2020.

  • Kepos Capital reported no remaining Pacific Biosciences position as of Q3 2020 after selling out during the quarter.
  • Kepos Capital sold 141,543 Pacific Biosciences shares in Q3 2020, an estimated $488K.
  • Kepos Capital first reported a position in Pacific Biosciences in Q1 2020 and held it in 2 quarters.
  • Kepos Capital's Pacific Biosciences position peaked at $488K in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2020.

Based on Kepos Capital's 13F filing for Q3 2020, filed 13 Nov 2020.